CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals Inc. (AMEX: JAV) today announced that it recently received notification that it had been granted a commercially important Canadian patent with broad claims, enabling greater protection of Javelin’s PMI-150 (intranasal ketamine). Canadian Patent Number 2,184,007 entitled: “Nasal and Ocular Administration of ketamine to manage Pain and for Detoxification” provides protection covering Javelin’s intranasal ketamine drug into 2015.
